Study drug for advanced cancers or relapsed AML
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Skin clinical trials.
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign consent before any study tests or procedures.
- You must be at least 18 (or 19 in some regions) when screened.
- For solid tumors: your cancer must be advanced/metastatic, incurable, and no longer responding to standard treatments (or you can’t tolerate them).
- For AML (substudy 4): you must have relapsed or refractory AML (not acute promyelocytic leukemia).
- You need blood counts and organ function strong enough for study treatment, based on lab tests.
- You must be able to do daily activities fairly well (ECOG performance status 0–1 for most parts; 0–2 for AML part).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
This study tests a new drug called BG-C0979 for advanced solid tumors that have not responded to standard treatments. It may be given alone or with other therapies to see if it can shrink tumors or slow cancer growth.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.